Key Highlights

  • SELLAS Life Sciences (NASDAQ:SLS) fell 15% to 16% on October 28, 2026, according to published market data, after the company said its REGAL trial reached the event count needed for final analysis.
  • The company said results are due this quarter, which ends December 31, 2026, so a binary clinical readout may arrive within about two months of the October 28 price move.
  • The same session saw Ginkgo Bioworks (NYSE:DNA) rise 19.8%, yet no company news explaining that jump was found, so the two moves should not be read as related.
  • Event-driven trials count patient events, such as deaths, before analysis can begin, so reaching the count means data are near, not that the result is positive.

What SELLAS Announced

SELLAS Life Sciences (NASDAQ:SLS) said in a company release that the REGAL trial had reached the number of events required for final analysis, and that results are expected this quarter. Published market data show the stock fell 15% to 16% on October 28, 2026. The release itself did not report efficacy, so the drop cannot be tied to any data. It is also not stated in the material reviewed whether the company gave a more precise date than this quarter. Investors therefore face a fixed deadline without knowing the outcome, which is why the shares can move sharply on the announcement alone, in either direction, before any result is public.

How Event Counts Work

In an event-driven trial, the statistical analysis is triggered by a prespecified number of events, such as deaths, instead of by a calendar date. Once the count is reached, the dataset is locked and independent statisticians compare the treatment and control arms. That is why SELLAS (NASDAQ:SLS) could say it had reached the milestone before knowing anything about the result. The step also removes the long wait that normally supports a share price, because the open question becomes a near-term binary test. One reading, offered as interpretation and not as a finding, is that some holders sold into the news to avoid the readout risk, though no confirmed reason for the decline was found.

Risks and What to Watch

Clinical readouts can disappoint, and a small biotech such as SELLAS Life Sciences (NASDAQ:SLS) often depends on equity raises to fund operations, which dilute existing holders. The material reviewed gave no cash figure for the company, so funding risk cannot be sized here. Ginkgo Bioworks (NYSE:DNA) moved the opposite way with a 19.8% gain and no news was found, which shows how unexplained single-stock swings can be. Watch for the results announcement, any change to the stated timeline, and any financing filed around the readout. A result is not guaranteed to arrive on schedule. Investors should also remember that a trial reaching its event count can still produce a neutral or negative result.

Where Things Stand

The shares of SELLAS Life Sciences (NASDAQ:SLS) fell 15% to 16% most likely because the REGAL trial moved from waiting to a near-term binary readout, though no explanation beyond the release is confirmed. The cause of the Ginkgo Bioworks (NYSE:DNA) gain was not verified. The next catalyst is the results announcement promised this quarter. Until then the stock carries the full uncertainty of a pivotal outcome. This is not investment advice.